Search Results - "Prost, Y de"

Subcutaneous fat necrosis of the newborn: a systematic evaluation of risk factors, clinical manifestations, complications and outcome of 16 children by Mahé, E., Girszyn, N., Hadj-Rabia, S., Bodemer, C., Hamel-Teillac, D., De Prost, Y.

“…Summary Background  Subcutaneous fat necrosis (SFN) of the newborn is a rare acute transient hypodermatitis that develops within the first weeks of life in…”
Get full text

International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies by Ellis, C., Luger, T., Abeck, D., Allen, R., Graham-Brown, R.A.C., De Prost, Y., Eichenfield, L.F., Ferrandiz, C., Giannetti, A., Hanifin, J., Koo, J.Y.M., Leung, D., Lynde, C., Ring, J., Ruiz-Maldonado, R., Saurat, J-H.

Get full text

Germline mosaicism in keratitis-ichthyosis-deafness syndrome: pre-natal diagnosis in a familial lethal form by Sbidian, E, Feldmann, D, Bengoa, J, Fraitag, S, Abadie, V, De Prost, Y, Bodemer, C, Hadj-Rabia, S

“…Sbidian E, Feldmann D, Bengoa J, Fraitag S, Abadie V, de Prost Y, Bodemer C, Hadj‐Rabia S. Germline mosaicism in keratitis–ichthyosis–deafness syndrome:…”
Get full text

Lymphomatoid papulosis in children: a series of 25 cases by Miquel, J., Fraitag, S., Hamel-Teillac, D., Molina, T., Brousse, N., de Prost, Y., Bodemer, C.

“…Summary Background Lymphomatoid papulosis (LyP) is an uncommon cutaneous T‐cell lymphoproliferative disorder (CTLPD) rarely encountered in children. Objectives…”
Get full text

Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome by Halabi-Tawil, M., Ruemmele, F.M., Fraitag, S., Rieux-Laucat, F., Neven, B., Brousse, N., De Prost, Y., Fischer, A., Goulet, O., Bodemer, C.

“…Summary Background  Immune dysregulation, polyendocrinopathy, enteropathy, X‐linked (IPEX) syndrome is a rare disorder characterized by neonatal autoimmune…”
Get full text

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme by Barbier, N., Paul, C., Luger, T., Allen, R., De Prost, Y., Papp, K., Eichenfield, L.f., Cherill, R., Hanifin, J.

“…Summary Objective  To validate the Eczema Area and Severity Index (EASI) by assessing its internal consistency, reliability and sensitivity to change and by…”
Get full text

New topical immunological treatments for psoriasis by De Prost, Y

“…Topical treatments for psoriasis have been used for a very long time. They were designed to reduce epidermal proliferation and hyperkeratosis. Recent…”
Get full text

Cervicofacial hemangioma and a minor sternal malformation : Inclusion in PHACES syndrome? by BOULINGUEZ, S, TEILLAC-HAMEL, D, BEDANE, C, BENNACEUR, S, DE PROST, Y

“…Hemangiomas are frequent in childhood, but those associated to dysmorphic anomalies are rare. We report a young girl with hemangiomas of the face, neck, and…”
Get full text

Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding by Colomb, V., Bourdon-Lannoy, E., Lambe, C., Sauvat, F., Hadj Rabia, S., Teillac, D., De Prost, Y., Bodemer, C.

“…Summary Background  Generalized recessive dystrophic epidermolysis bullosa (RDEB) is often complicated by high nutritional difficulties with risks of…”
Get full text

Recurrent nonsense mutations within the type VII collagen gene in patients with severe recessive dystrophic epidermolysis bullosa by HOVNANIAN, A, LATIFA HILAL, BLANCHET-BARDON, C, DE PROST, Y, CHRISTIANO, A. M, UITTO, J, GOOSSENS, M

“…The generalized mutilating form of recessive dystrophic epidermolysis bullosa (i.e., the Hallopeau-Siemens type; HS-RDEB) is a life-threatening disease…”
Get full text

Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life by McKenna, SP, Whalley, D, de Prost, Y, Staab, D, Huels, J, Paul, CF, van Assche, D

“…Aim  To report on quality of life (QoL) and health‐related quality of life (HRQL) impacts of pimecrolimus (Elidel®, Novartis A.G., Basel, Switzerland, SDZ ASM…”
Get full text

Consensus statement on the safety profile of topical calcineurin inhibitors by Bieber, T, Cork, M, Ellis, C, Girolomoni, G, Groves, R, Langley, R, Luger, T, Meurer, M, Murrell, D, Orlow, S, Paller, A, de Prost, Y, Puig, L, Ring, J, Saurat, J-H, Schwarz, T, Shear, N, Stingl, G, Taieb, A, Thestrup-Pedersen, K

Get more information

Absence of anti-BP180 antibodies in mothers of infants with bullous pemphigoid by Chiavérini, C., Hamel-Teillac, D., Gilbert, D., de Prost, Y.

“…Summary Background  It is not clear whether bullous pemphigoid (BP) of infancy is linked to maternal transmission of pathogenic autoantibodies. Objectives  To…”
Get full text

High frequency of detection of human papillomaviruses associated with epidermodysplasia verruciformis in children with psoriasis by Mahé, E., Bodemer, C., Descamps, V., Mahé, I., Crickx, B., De Prost, Y., Favre, M.

“…Summary Background  Psoriasis is a T‐cell‐mediated immunological disease characterized by epidermal proliferation. The nature of the antigen(s) responsible for…”
Get full text

Genetic bases of severe junctional epidermolysis bullosa presenting spontaneous amelioration with aging by GACHE, Y, ALLEGRA, M, BODEMER, C, PISANI-SPADAFORA, A, DE PROST, Y, ORTONNE, J. P, MENEGUZZI, G

“…Change of the clinical picture with aging is noted in some patients suffering from junctional epidermolysis bullosa (JEB), an inherited blistering disorder…”
Get full text

First fixed drug eruption due to teicoplanin with a peri-oral distribution by Duong, T, Hamel, D, Benlahrech, S, Le Quan Sang, KH, Sauvé-Martin, H, De Prost, Y, Roujeau, JC, Hadj-Rabia, S

Get full text

Efficacy of intravenous immunoglobulins in sclerodermatomyositis by Bodemer, C, Teillac, D, Le Bourgeois, M, Wechsler, B, de Prost, Y

Get more information

Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment by Doss, N., Kamoun, M.-R., Dubertret, L., Cambazard, F., Remitz, A., Lahfa, M., De Prost, Y.

“…Doss N, Kamoun M‐R, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with…”
Get full text

Sirolimus-induced onychopathy in renal transplant recipients by Mahé, E, Morelon, E, Lechaton, S, Kreis, H, De Prost, Y, Bodemer, C

“…A large number of drugs may be responsible for the development of nail changes. Sirolimus is an immunosuppressive drug recently developed in organ…”
Get full text

Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis by Bitoun, E., Bodemer, C., Amiel, J., de Prost, Y., Stoll, C., Calvas, P., Hovnanian, A.

“…Netherton syndrome (NS) is a severe autosomal recessive ichthyosis with no specific treatment or prenatal diagnosis available at present. The recent…”
Get full text